Biotech News

Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics

Seer, Inc (SEER)Seer, IncCompany update

ITC investigative staff recommends full exclusion and cease-and-desist orders sought by Seer REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced a significant victory in its patent

Related news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

Stock data

Close
1.39 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States